Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 25, 2012
Karyopharm Therapeutics Announces Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid Tumor Models at the American Society of Clinical Oncology (ASCO) MeetingNatick, Mass. May...
-
May 8, 2012
Karyopharm Therapeutics Announces Appointment of Cofounder Dr. Ronald DePinho to the National Academy of SciencesNatick, Mass. May 8, 2012 Karyopharm Therapeutics Inc., a leader in the new field...
-
Mar 15, 2012
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American...
-
Nov 8, 2011
Karyopharm Therapeutics Announces Presentations by Seven Collaborators showing Major Progress in advancing Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at American...
-
Nov 2, 2011
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for CancerNatick, Mass. – November 2, 2011...
-
Oct 11, 2011Karyopharm Therapeutics Inc. and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
Natick, Mass. – October 11, 2011 Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has initiated an exclusive collaboration in the area of Selective...
-
Jan 6, 2011
Multiple Myeloma Research Foundation (MMRF) Invests $3 Million in Development of Next-Generation TreatmentsNorwalk, Conn. – January 6, 2011 The Multiple Myeloma Research Foundation (MMRF) today...
-
Jan 5, 2011
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive OfficerNewton, Mass. – January 5, 2011 Karyopharm Therapeutics Inc., a pioneer and leader in the new field of...
-
Nov 3, 2010
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other DisordersNewton, Mass. – November...